Neurocrine Biosciences Inc (NBIX)

Receivables turnover

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Revenue (ttm)	US$ in thousands	1,882,900	1,779,300	1,668,300	1,522,900	1,411,600	1,306,100	1,208,800	1,185,500	1,107,700	1,050,200	1,010,800	1,022,200	1,020,900	1,017,010	981,066	862,604	764,254	651,736	581,765	503,032
Receivables	US$ in thousands	439,300	425,900	393,200	396,000	350,000	305,100	281,700	266,500	187,700	166,600	161,200	151,000	160,800	160,400	152,100	153,300	126,575	115,318	95,357	71,964
Receivables turnover		4.29	4.18	4.24	3.85	4.03	4.28	4.29	4.45	5.90	6.30	6.27	6.77	6.35	6.34	6.45	5.63	6.04	5.65	6.10	6.99

December 31, 2023 calculation

Receivables turnover = Revenue (ttm) ÷ Receivables
= $1,882,900K ÷ $439,300K
= 4.29

Neurocrine Biosciences, Inc.'s receivables turnover has shown fluctuation over the past eight quarters. The company's receivables turnover ratio ranged from a low of 4.08 in Q1 2023 to a high of 4.65 in Q3 2022. Overall, the average receivables turnover ratio over this period is approximately 4.41.

A higher receivables turnover ratio indicates that Neurocrine Biosciences, Inc. is efficient in collecting payments from its customers. The decreasing trend in the receivables turnover ratio in recent quarters may suggest a slowdown in collecting accounts receivable, which could potentially impact the company's cash flows and liquidity position.

It would be prudent for stakeholders to closely monitor Neurocrine Biosciences, Inc.'s collection processes and implement strategies to improve the efficiency of accounts receivable management to maintain stable cash flows and financial health.